FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2024年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | | 1 RMB | | 95,140,500 | | 2. ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the first half of 2024 is under pressure, with a significant decline in domestic revenue, while overseas market growth is strong, achieving a revenue of 1.55 billion yuan, a year-on-year increase of 82% [1][2] - The company is focusing on expanding its product lines in the orthopedic field, including innovations in joint products and the development of surgical robots, which enhances surgical precision and promotes minimally invasive procedures [2][3] Financial Performance Summary - In the first half of 2024, the company reported a revenue of 380 million yuan, a year-on-year decline of 46.23%, and a net profit attributable to shareholders of 79.03 million yuan, down 37.32% [1] - The company expects revenues for 2024-2026 to be 1.285 billion yuan, 1.577 billion yuan, and 1.970 billion yuan, with growth rates of 6.4%, 22.7%, and 24.9% respectively [3][5] - The projected net profit for the same period is 262 million yuan, 352 million yuan, and 451 million yuan, with growth rates of -5.7%, 34.2%, and 28.3% respectively [3][5] Product Development and Market Expansion - The company has successfully registered multiple products in overseas markets and has received CE certification for its orthopedic products, as well as FDA approval for its knee joint prosthesis system [1][2] - The company is expanding its product offerings in the dental field, including dental implants and orthodontic products, aiming to create a comprehensive oral health solution [2]

证券代码：688236 证券简称：春立医疗 公告编号：2024-035 北京市春立正达医疗器械股份有限公司 关于以集中竞价交易方式回购公司股份的回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2024 年 7 | 月 | 5 日 | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 6 | 月 | 17 日-2025 年 6 月 16 日 | | | 预计回购金额 | 2000 万元-4000 | | 万元 | | | 回购用途 | | | 用于员工持股计划或股权激励 | | | 累计已回购股数 | 272,145 | 股 | | | | 累计已回购股数占总股本比例 | 0.071% | | | | | 累计已回购金额 | 3,654,906.79 | | 元 | | | 实际回购价格区间 | 12.09 | | 元/股 | 元/股-14.16 | 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司 ...

如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股、回购 股份、股权激励授予股份回购注销、重大资产重组股份回购注销等致使公司总股本 发生变动的，公司拟维持每股派发现金红利金额不变，相应调整分配的总额， 并将 证券代码：688236 证券简称：春立医疗 公告编号：2024-028 北京市春立正达医疗器械股份有限公司 2024 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 北京市春立正达医疗器械股份有限公司（以下简称"公司"）2024 年半年度实现 归属于母公司所有者的净利润为人民币 79,026,078.82 元。根据中国证券监督管理 委员会《关于进一步落实上市公司现金分红有关事项的通知》、《上市公司监管指引 第 3 号—上市公司现金分红》等有关规定及《公司章程》的相关规定，经综合考虑 投资者的合理回报和公司的长远发展，在保证公司正常经营业务发展的前提下，经 董事会决议，公司 2024 年半年度拟以实施权益分派股权登记日登记的总股本扣除回 购专户持 ...

北京市春立正达医疗器械股份公司 2024 年度提质增效重回报专项行动方案的 半年度评估报告 为践行以"投资者为本"的上市公司发展理念，维护公司全体股东的利益，基于对 经营状况和未来发展前景的信心，围绕立足主业、提升科技创新水平、回报股东、加强 投资者沟通等方面，北京市春立正达医疗器械股份公司（以下简称"公司"或"春立医 疗"）于 2024 年 3 月 29 日发布了《2024 年度"提质增效重回报"行动方案》（以下简称 "行动方案"），以进一步优化经营效率、强化市场竞争力，保障投资者权益，树立良好 的资本市场形象。2024 年上半年，公司根据行动方案内容，积极开展和落实各项工作， 现将行动方案在报告期内的 实施和效果评估情况报告如下： 一、 聚焦主业发展，持续创新研发，扩充产品线 公司主要从事骨科耗材的研发、生产及销售。2024 年上半年，公司围绕行动方案的 战略方向，积极聚焦主营业务，持续创新研发投入，全面提升公司的核心竞争力，不断 突破创新，快速扩增产品线及扩大产品在国内外的市场占有率。 公司始终高度重视技术创新和研发体系建设，以保证技术和产品持续创新，提高产 品市场竞争优势。公司作为"十三五"G20 创 ...

证券代码：688236 证券简称：春立医疗 公告编号：2024-029 北京市春立正达医疗器械股份有限公司 第五届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 北京市春立正达医疗器械股份有限公司（以下简称"公司"）第五届董事会 第十六次会议于2024年8月30日以现场加通讯方式召开。本次会议通知已于2024 年 8 月 21 日发出。本次会议由公司董事长史文玲女士召集并主持，会议应出席董 事 8 名，实际出席董事 8 名。本次会议的召集、召开和表决程序符合《中华人民 共和国公司法》等法律、行政法规、部门规章、规范性文件和《公司章程》的相 关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事审议，以记名投票的方式一致通过以下议案： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 公司 2024 年半年度报告的编制和审核程序符合法律、法规及《公司章程》、 公司内部管理制度的各项规定。公允地反映了公司 2024 年半年度的财务状况和经 营成果等 ...

证券代码：688236 证券简称：春立医疗 公告编号：2024-033 北京市春立正达医疗器械股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）自 2023 年 7 月 28 日 至本公告披露日，收到国家药品监督管理局、北京市药品监督管理局、河北省药品监督 管理局、北京市通州区市场监督管理局颁发的 52 款产品的医疗器械注册证或备案凭证， 具体情况公告如下： 一、 医疗器械注册证及备案凭证的具体情况 （一） 关节产品线 | 注册证编号 | 序号 注册证产品名称 | | | | | | 发证机构 | | --- | --- | --- | --- | --- | --- | --- | --- | | 国械注准 20233131076 | 1 髋关节假体-翻修股骨柄 | | | | | | 国家药品监督管理局 | | 8 年 7 31 日 | 注册证有效期：2023 | 年 | 月 | 1 | 日-2028 | 月 | | ...

Financial Performance - The net profit attributable to the parent company for the first half of 2024 was RMB 79,026,078.82, with a cash dividend distribution plan of RMB 0.83 per share (including tax) for every 10 shares[5]. - The company's revenue for the first half of 2024 was approximately ¥380.13 million, a decrease of 29.70% compared to ¥540.71 million in the same period last year[21]. - The net profit attributable to shareholders for the same period was ¥79.03 million, down 37.32% from ¥126.08 million year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥65.91 million, a decline of 40.25% compared to ¥110.32 million in the previous year[21]. - The company's operating cash flow for the first half of 2024 was negative at ¥69.06 million, compared to a negative ¥38.97 million in the same period last year[22]. - The total assets at the end of the reporting period were approximately ¥3.63 billion, a decrease of 0.46% from ¥3.65 billion at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 2.08% to ¥2.82 billion from ¥2.88 billion at the end of the previous year[22]. - Basic earnings per share for the first half of 2024 were ¥0.21, down 36.36% from ¥0.33 in the same period last year[23]. - The company's total operating revenue for the first half of 2024 was CNY 380,130,570.92, a decrease of 29.70% compared to the same period last year[75]. - The net profit attributable to shareholders was CNY 79,026,078.82, down 37.32% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 40.25% to CNY 65,914,992.65[75]. Dividend and Share Capital - The total share capital as of July 31, 2024, was 383,568,500 shares, with 383,341,355 shares eligible for profit distribution after excluding repurchased shares[5]. - The cash dividend amount represents 40.26% of the net profit attributable to shareholders of the listed company in the consolidated financial statements[5]. - The board of directors has approved the profit distribution plan, pending approval at the 2024 interim shareholders' meeting[5]. - The company does not plan to increase capital reserves or issue bonus shares during this period[5]. Research and Development - The R&D expenditure as a percentage of revenue increased to 17.80%, up 4.01 percentage points from 13.79% in the previous year[23]. - The total R&D expenditure for the first half of 2024 reached 67.6 million, a 10.5% increase from 61.24 million in the same period last year[57]. - The company has reduced its R&D personnel from 462 to 381, resulting in a decrease in the proportion of R&D staff from 33.5% to 29.51% of total employees[58]. - The average salary for R&D personnel increased from 6.56 million to 7.98 million, reflecting a focus on retaining skilled talent[58]. - The company has registered multiple patents, including 36 new invention patent applications and 24 granted patents during the reporting period, totaling 1,080 applications and 606 granted patents[52]. Market and Product Development - The company is a leading domestic manufacturer of orthopedic medical devices, focusing on implantable orthopedic products, including joint, spine, trauma, and sports medicine devices[26]. - The company is actively expanding its product line with new materials and technologies, including the development of porous tantalum, magnesium alloys, and PEEK[27]. - The company has developed a surgical robot for hip and knee replacements, which is the first of its kind approved internationally[28]. - The company is committed to expanding its international market presence while maintaining its leading position in the domestic market[27]. - The company has launched multiple trauma series products, including trauma osteotomy and intramedullary fixation products, with a market potential that remains unsaturated[56]. Risks and Compliance - The company has described potential significant risks in the report, which investors should review[3]. - The report includes forward-looking statements regarding future plans and development strategies, which do not constitute a substantive commitment to investors[7]. - The company faces risks related to the long and costly product registration process, which may affect its future growth potential if new products fail to gain approval[70]. - Regulatory changes in the medical device industry may impose additional compliance requirements, affecting the company's operations if not met[74]. - The company is closely monitoring centralized procurement policies to mitigate potential impacts on product pricing and gross margins[73]. Environmental and Social Responsibility - The company invested 6.32 million CNY in environmental protection during the reporting period[99]. - The company has established an environmental protection management system and complies with applicable environmental laws and regulations[101]. - The company has implemented measures to reduce waste and recycle materials, including selling recyclable waste materials[101]. - The company has constructed solar power generation facilities at its new production base to support future energy savings[102]. Corporate Governance - The company held its 2023 Annual General Meeting on June 27, 2024, where all proposed resolutions were approved, including the profit distribution plan for 2023[95]. - The company appointed Xu Hong as an independent director on June 27, 2024, following the resignation of independent director Yao Lijie[96]. - The company has made commitments regarding information disclosure to shareholders, ensuring transparency and compliance with regulations[107]. - The company has outlined measures to compensate for any losses incurred by shareholders due to non-compliance with commitments made by the controlling shareholders[107]. Financial Management - The total amount of raised funds is CNY 1,145,538,680, with a net amount after issuance costs of CNY 1,067,128,292.23[116]. - The cumulative investment of raised funds reached CNY 404,068,889.86, representing 37.87% of the total raised funds[116]. - The company has utilized CNY 71,000 for cash management, with a cash management balance of CNY 61,500 at the end of the reporting period[124]. - The company reported a significant increase in other payables, which reached CNY 195,764,287.77, up 195.21% year-on-year, mainly due to the distribution of cash dividends[78].

证券代码：688236 证券简称：春立医疗 公告编号：2024-034 北京市春立正达医疗器械股份有限公司 关于募投项目延期及变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2024 年 8 月 30 日 召开第五届董事会第十六会议、第五届监事会第十次会议，审议通过了《关于募投项 目延期及变更的议案》，同意公司对募投项目达到预定可使用状态的时间进行延期， 以及增加项目实施主体、实施地点等方式的调整。保荐机构华泰联合证券有限责任公 司（以下简称"保荐机构"）对本事项出具了无异议的核查意见。该事项尚需提交公司 股东大会审议。 现将相关情况公告如下： 一、 募集资金基本情况 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管理委 员会出具证监许可〔2021〕3702 号同意注册文件，公司获准向社会公众公开发行人民 币普通股（A 股）股票 38,428,000 股，每股面值人民币 1.00 元，发行价格为每股人 民币 29.81 元，募集资金总额 ...

二、募集资金投资项目情况和使用及闲置原因 截至 2024 年 6 月 30 日公司投入到募投项目资金总额 404,068,889.86 元，用 于现金管理的金额为 615,000,000.00 元，公司募集资金账户余额为 95,730,960.14 1 核查意见 华泰联合证券有限责任公司关于 北京市春立正达医疗器械股份有限公司使用部分闲置募集 资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"）作为北京市春立 正达医疗器械股份有限公司（以下简称"春立医疗"或"公司"）首次公开发行 股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管 理办法》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》、《上海证券交易所科创板股票上市规则》、《上海证券交易所 科创板上市公司自律监管指引第 1 号—规范运作》等有关规定，对春立医疗拟使 用部分闲置募集资金进行现金管理的事项进行了审慎核查，核查情况及核查意见 如下： 一、募集资金的基本情况 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021 ...